Immediate Impact
3 from Science/Nature 53 standout
Citing Papers
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
2024 Standout
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2023 Standout
Works of Y-L. Chan being referenced
IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis.
1977
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Y-L. Chan | 61 | 302 | 103 | 95 | 12 | 444 | |
| G.B. Fogazzi | 37 | 331 | 126 | 77 | 14 | 418 | |
| Job D. Elema | 91 | 218 | 156 | 64 | 14 | 510 | |
| Rossana Faedda | 79 | 173 | 90 | 60 | 23 | 430 | |
| Emilio Rivolta | 65 | 288 | 71 | 100 | 10 | 408 | |
| Angelo Testa | 75 | 322 | 111 | 77 | 14 | 453 | |
| Couser Wg | 115 | 305 | 92 | 38 | 14 | 507 | |
| Christian Brown | 72 | 174 | 199 | 37 | 19 | 491 | |
| Christos Bantis | 55 | 209 | 68 | 45 | 21 | 389 | |
| Yasushi Koitabashi | 71 | 194 | 103 | 48 | 21 | 406 | |
| G Pannarale | 176 | 154 | 113 | 94 | 15 | 490 |
All Works
Loading papers...